| Similar Articles |
|---|
 |
Chemistry World
February 12, 2014
Amy Middleton-Gear |
Neutralizing heparin without complications Recovering from operations could become easier thanks to a self-assembling multivalent heparin binding agent being developed by scientists in the UK, Italy and Spain.   |
Chemistry World
August 19, 2008
Ananyo Bhattacharya |
Flask synthesis promises untainted heparin US researchers have created milligrams of pure heparin using enzymes and chemicals - a practical laboratory synthesis that could avoid the contamination issues surrounding the blood-thinning drug |
Chemistry World
April 20, 2011
Jon Cartwright |
New clotting drug antidote could cut surgery risk Chemists in the UK have developed a possible alternative to protamine, a molecule used by doctors to counteract the effects of anti-clotting drugs. |
The Motley Fool
April 10, 2008
Brian Orelli |
The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company. |
Chemistry World
October 28, 2011
James Urquhart |
Simpler Enzymatic Route to Synthetic Heparin US scientists have demonstrated a potentially cheaper way of creating ultra low molecular weight heparin, a synthetic blood thinning agent primarily used to treat deep vein thrombosis and pulmonary embolism. |
Nursing
February 2012
Pezzotti & Freuler |
Using anticoagulants to steer clear of clots This article will review coagulation and provide important information about several commonly used anticoagulants and their reversal agents. |
The Motley Fool
April 2, 2008
Brian Lawler |
Medicines Company Sets Itself Apart Drugmaker Medicines Company wants to distance its angioplasty treatment from heparin. |
Chemistry World
January 18, 2013
Emma Eley |
New method to target malaria Malaria affects millions of people each year; however, no effective vaccines exist. Now, scientists from Spain have discovered a new strategy to target the disease. |
The Motley Fool
March 7, 2008
Brian Lawler |
A Little Too Much Drug Variability Another drugmaker has to recall batches of its compound. |
American Family Physician
June 15, 2004
Ramzi & Leeper |
DVT and Pulmonary Embolism: Part II. Treatment and Prevention Evaluation for thrombophilias and other secondary causes of venous thromboembolic disease, presents an evidence-based approach to the treatment of DVT and PE, and reviews current recommendations for prevention of venous thromboembolism. |
American Family Physician
March 15, 2002
Khalid Almoosa |
Is Thrombolytic Therapy Effective for Pulmonary Embolism? No evidence from clinical trials proves that thrombolytic therapy reduces the recurrence rate of pulmonary embolism or affects mortality in hemodynamically stable patients... |
The Motley Fool
February 29, 2008
Brian Orelli |
Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried. |
American Family Physician
July 15, 2002
Dana E. King |
Acute Management of Atrial Fibrillation: Part II. Prevention of Thromboembolic Complications Family physicians should be familiar with the acute management of atrial fibrillation and the initiation of chronic therapy for this common arrhythmia. Part II of this two-part article focuses on the prevention of thromboembolic complications using anticoagulation. |
Chemistry World
September 17, 2013
Laura Howes |
What happens when you perturb the system? David Smith is a professor of chemistry at the University of York in the UK. His research explores how supramolecular chemistry can make molecular-scale building blocks self-assemble into nanostructures. He also has a passion for educational outreach. |
Chemistry World
August 11, 2015
Emma Cooper |
Streamlined synthesis yields longer sugar chains By using bigger building blocks, scientists in the UK have shown they can make much longer oligosaccharide sequences than previously possible. |
